Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.19.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 10,525 $ 5,704 $ 19,154 $ 11,497
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 10,525 5,704 19,154 11,497
Collaboration and License Agreements and Supply Agreements | Celgene        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,670 2,835 3,245 6,919
Collaboration and License Agreements and Supply Agreements | Merck        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 5,497 0 10,132 0
Collaboration and License Agreements and Supply Agreements | SutroVax        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 0 902 281 902
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany “EMD Serono”)        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 3,358 $ 1,967 $ 5,496 $ 3,676